RxDoctor Payments Data

Jay Schlaifer, MD

Interventional Cardiology · Lafayette, INNPI 1841251592

Payments from drug & device makers

$11,194in general payments, 2019–2025

Across 67 payments — averaging $167.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Research Incorporated$8K
  • Medtronic$733
  • Biotronik Inc.$469
  • Shockwave Medical, Inc$416
  • Boston Scientific$407
  • Abbott$339
  • plus $855 from 8 others

What the payments were for

  • Consulting fees$7,97571%
  • Food & beverage$3,21929%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,194 in reported general payments places this provider in the 55th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$182,612
Medicare patients
670
Services billed
1,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban367$415,111
XareltoRivaroxaban165$197,546
JardianceEmpagliflozin117$164,221
EntrestoSacubitril/Valsartan93$122,245
Repatha SureclickEvolocumab80$86,426
FarxigaDapagliflozin Propanediol60$57,885
OzempicSemaglutide42$48,703
BrilintaTicagrelor22$24,830
NexletolBempedoic Acid16$13,068
Ranolazine ErRanolazine50$10,300
VascepaIcosapent Ethyl15$7,599
Ezetimibe317$6,767
Atorvastatin Calcium647$6,230
Metoprolol Succinate470$6,064
Flecainide Acetate75$5,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$83$197,546165 claims
NovartisEntresto$17$122,24593 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →